Onsetron (Ondansetron)

Ondansetron, the active ingredient in Onsetron, is a 5‑HT3 receptor antagonist presented as an oral tablet for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult patients, improving comfort during cancer treatment and surgery.

GNH USA supplies Onsetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide through regulated distribution channels.

Onsetron (ondansetron) is used to manage nausea and vomiting across several therapeutic areas.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed nausea and vomiting in patients receiving moderately to highly emetogenic cancer chemotherapy. Radiotherapy‑induced nausea and vomiting: helps prevent nausea and vomiting that can occur during or after radiation treatment, particularly when combined with chemotherapy. Postoperative nausea and vomiting: administered before surgery to lower the risk of nausea and vomiting during the recovery period after general anesthesia.

Common Side Effects: - Headache - Constipation - Diarrhea - Dizziness - Fatigue - Abdominal pain

Serious or Rare Side Effects: - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reactions such as anaphylaxis - Serotonin syndrome when combined with other serotonergic agents - Severe skin reactions including Stevens‑Johnson syndrome - Hepatic enzyme elevation or liver injury - Neutropenia or other blood dyscrasias

Precautions should be observed when prescribing Onsetron. - Assess cardiac risk: evaluate baseline ECG for QT prolongation before initiating therapy. - Monitor electrolytes: correct hypokalemia, hypomagnesemia, and hypocalcemia which can increase cardiac risk. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant use with other QT‑prolonging agents unless benefits outweigh risks. - Pregnancy and lactation: consider risk‑benefit assessment as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Onsetron may interact with other medicines. Major Interactions (Avoid): - Apomorphine: concurrent use can cause severe hypotension and loss of consciousness. - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): may increase risk of cardiac arrhythmias. - Serotonergic agents (e.g., SSRIs, MAO inhibitors) when combined with additional serotonergic drugs can precipitate serotonin syndrome. Moderate Interactions (Monitor Closely): - Dexamethasone and other corticosteroids: may enhance antiemetic effect but require monitoring. - Erythromycin and other CYP3A4 inhibitors: can increase ondansetron plasma levels. - Oral contraceptives: may reduce efficacy of hormonal contraception.